Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s lead product candidate, gedatolisib, is designed to inhibit the PI3K/AKT/mTOR signaling pathway, which plays a central role in cancer cell growth and survival. Celcuity’s current research and development efforts are centered on breast and prostate cancers, with additional work in other tumor types linked to the same pathway. The company also develops the CELsignia companion diagnostic platform, which analyzes live tumor cells to help identify patient groups that may benefit from targeted cancer treatments. Based in Minneapolis, Minnesota, Celcuity operates as a precision oncology company aiming to improve how cellular abnormalities are detected and addressed in cancer care.